Zepsyre fails in Phase III trial for ovarian cancer.- Pharma Mar, S.A.
Pharma Mar, S.A. announces the results of the Phase III clinical trial (CORAIL) with Zepsyre (lurbinectedin) in platinum-resistant ovarian cancer patients. The CORAIL trial, comparing Zepsyre versus topotecan or PLD (liposomal doxorubicin) in platinum resistant ovarian cancer patients has not met the primary end-point of the trial, which was PFS (Progression Free Survival).
The antitumoral activity of the three compounds Zepsyre, topotecan and PLD, in terms of PFS, has been the same. In the CORAIL trial Zepsyre has demonstrated a better safety profile than the control arm. Results of this trial will be presented at future oncology congresses.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.